Azerbaijan vs Sri Lanka: Hepatitis B surface antigen (HBsAg) prevalence
Azerbaijan
0.3%
in 2024
Sri Lanka
0.3%
in 2024
Azerbaijan rank
71st
Sri Lanka rank
71st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Azerbaijan
- Sri Lanka
How they compare
Azerbaijan currently reports 0.3% against 0.3% in Sri Lanka, a difference of 0.0%.
Across all 10 years both countries report, Sri Lanka has been ahead every year.
Azerbaijan ranks 71st and Sri Lanka ranks 71st of 194 countries.
Sri Lanka has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Azerbaijan | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | Sri Lanka |
| 2020s | 0.3% | 0.3% | 0.0% | Sri Lanka |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Azerbaijan or Sri Lanka?
- Azerbaijan, at 0.3% against 0.3% in Sri Lanka as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Azerbaijan and Sri Lanka?
- 0.0%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Sri Lanka?
- 10 years are reported by both, from 2015 to 2024.
- How do Azerbaijan and Sri Lanka rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Azerbaijan ranks 71st and Sri Lanka ranks 71st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.